Scott C. Jamerson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott C. Jamerson has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Brian D. Ellis
West Virginia University
1 shared publicationGuruswami Arunagiri
West Virginia University
1 shared publicationMonique J. Leys
West Virginia University
1 shared publication
Latest Publications
- 15 January 2008
- Published by Springer Nature in International Ophthalmology
- Vol. 29 (3) , 183-185
Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri
Background In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema. Case report We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).
- 15 January 2008
- Published by Springer Nature in International Ophthalmology
- Vol. 29 (3) , 183-185
Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri
Background In pseudotumor cerebri (PTC), elevated intracranial pressure (ICP) results in papilledema and, rarely, choroidal neovascularization (CNV). Pseudotumor cerebri-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary. Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve edema. Case report We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA).